IGC Pharma Inc (IGC)

IGC Pharma Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Revenue	1.35	1.35	0.91	0.4	0.9	4.07
Revenue Growth (YoY)	47.64%	47.64%	129.47%	-55.79%	-77.95%	-20.41%
Cost of Revenue	0.61	0.61	0.47	0.2	0.79	3.96
Gross Profit	0.73	0.73	0.44	0.19	0.11	0.12
Selling, General & Admin	6.76	6.76	8.55	13.29	7.91	5.97
Research & Development	3.77	3.77	3.46	2.33	0.93	1.01
Operating Expenses	10.53	10.53	12.01	15.62	8.84	6.98
Operating Income	-9.8	-9.8	-11.57	-15.43	-8.72	-6.86
Other Expense / Income	3.2	3.2	-0.07	-0.41	0.09	0.45
Pretax Income	-13	-13	-11.51	-15.02	-8.81	-7.32
Net Income	-13	-13	-11.51	-15.02	-8.81	-7.32
Shares Outstanding (Basic)	59	59	53	50	42	39
Shares Outstanding (Diluted)	59	59	53	50	42	39
Shares Change	11.91%	11.91%	5.17%	19.13%	6.26%	11.58%
EPS (Basic)	-0.22	-0.22	-0.22	-0.30	-0.21	-0.19
EPS (Diluted)	-0.22	-0.22	-0.22	-0.30	-0.21	-0.19
Free Cash Flow	-5.29	-5.29	-6.82	-7.67	-12.27	-13.07
Free Cash Flow Per Share	-0.09	-0.09	-0.13	-0.15	-0.29	-0.33
Gross Margin	54.50%	54.50%	48.52%	48.87%	12.58%	2.82%
Operating Margin	-728.48%	-728.48%	-1270.14%	-3886.15%	-971.49%	-168.57%
Profit Margin	-966.54%	-966.54%	-1263.01%	-3782.37%	-981.18%	-179.64%
Free Cash Flow Margin	-393.53%	-393.53%	-748.52%	-1931.74%	-1366.37%	-320.87%
EBITDA	-12.36	-12.36	-10.85	-14.37	-8.33	-7.17
EBITDA Margin	-919.18%	-919.18%	-1190.89%	-3618.39%	-927.95%	-176.11%
Depreciation & Amortization	0.64	0.64	0.66	0.65	0.48	0.14
EBIT	-13	-13	-11.51	-15.02	-8.81	-7.32
EBIT Margin	-966.54%	-966.54%	-1263.01%	-3782.37%	-981.18%	-179.64%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).